Publikationer

This article explains the evaluation carried out in the MATRIX study on the clinical value of intensive cardiac surveillance in low- to intermediate-risk lymphoma patients receiving anthracycline-based chemotherapy. Among 44 patients followed for 10 months, no cases of symptomatic heart failure, cardiovascular death, or major cardiovascular events were observed. Although

Anthracyclines are among the most widely used chemotherapy drugs and have been a mainstay of cancer treatment for more than 30 years. Their extraordinary efficacy against numerous solid and hematologic tumors means that they remain first-line drugs today, administered alone or in combination with other therapies. Anthracyclines continue to be

Colorectal cancer is the third most common cancer and second leading cause of cancer-related death worldwide. Standard management of stage III or high-risk stage II colon cancer includes surgery followed by 3 to 6 months of treatments. Despite these treatments, recurrent disease develops in 20 to 40% of the patients.

Anthracyclines, alone or in combination, remain the first-line therapy for many cancers, including various forms of lymphoma, breast cancer, leukaemia, melanoma, and uterine and gastric cancers. Every year, anthracyclines are administered to >3 million European citizens to treat a first cancer. The curative potential of anthracycline therapy is determined by

GCOS 2023 Symposium Proceedings: JACC: CardioOncology State-of-the-Art Review Despite improvements in cancer survival, cancer therapy–related cardiovascular toxicity has risen to become a prominent clinical challenge. This has led to the growth of the burgeoning field of cardio-oncology, which aims to advance the cardiovascular health of cancer patients and survivors, through

This article is authored by 2 PIs of RESILIENCE (María Gomes-Silva from IPO Lisbon & Borja Ibanez from CNIC Spain). This editorial summarizes the results of the 2 first trials testing remote ischemic conditioning in the context of anthracycline cardiotoxicity. In this article, the 2 trials are described and their